{"product_id":"bway-vrio-analysis","title":"BrainsWay Ltd. (BWAY): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eWhat truly fuels BrainsWay Ltd. (BWAY)'s success? This VRIO analysis distills their entire competitive landscape down to four critical questions: Are their assets Valuable, Rare, Inimitable, and Organized? Dive in now to uncover the precise sources of their sustainable advantage and see exactly where they stand against the competition.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBrainsWay Ltd. (BWAY) - VRIO Analysis: Proprietary Deep TMS Technology Platform\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core engine of BrainsWay Ltd. (BWAY), the Deep TMS platform, and wondering if it’s truly defensible. Honestly, based on the latest numbers, it looks like a keeper. The technology isn't just a nice-to-have; it’s driving real, measurable financial results right now.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Core Revenue Driver\u003c\/h3\u003e\n\u003cp\u003eThe Deep TMS platform is definitely valuable because it’s the mechanism generating the top-line growth you need to see. It directly translates into revenue from system sales and leases. For the third quarter of fiscal year 2025, this platform was responsible for revenue hitting \u003cstrong\u003e$13.5 million\u003c\/strong\u003e, a solid \u003cstrong\u003e29%\u003c\/strong\u003e increase year-over-year. That’s not abstract; that’s cash flow supporting operations, which saw an operating income of \u003cstrong\u003e$1.3 million\u003c\/strong\u003e in the same quarter.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on its impact:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQ3 2025 Revenue: \u003cstrong\u003e$13.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSystems Shipped Q3 2025: \u003cstrong\u003e90\u003c\/strong\u003e units.\u003c\/li\u003e\n\u003cli\u003eTotal Installed Base: Over \u003cstrong\u003e1,600\u003c\/strong\u003e systems globally.\u003c\/li\u003e\n\u003cli\u003eGross Margin on Sales: A strong \u003cstrong\u003e75%\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eWhat this estimate hides is the long-term value locked in the multi-year contracts; the Remaining Performance Obligations stand at \u003cstrong\u003e$65 million\u003c\/strong\u003e, showing customers are committed well into the future.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Deeper Reach is Uncommon\u003c\/h3\u003e\n\u003cp\u003eYes, the Deep TMS platform is rare because it targets deeper brain structures compared to older Transcranial Magnetic Stimulation (TMS) devices. In the current market landscape as of late 2025, few competitors have achieved this specific technological feat with the same clinical backing. The fact that BrainsWay Ltd. secured FDA clearance for an accelerated protocol for Major Depressive Disorder (MDD) in Q3 2025 further underscores the unique regulatory and technical standing of this technology. It’s not just a different coil; it’s a different level of access.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: High Barrier to Entry\u003c\/h3\u003e\n\u003cp\u003eReplicating this technology is tough, which means imitability is high. It’s not just about reverse-engineering the hardware. You’re looking at years of specialized engineering, clinical validation, and navigating complex regulatory pathways, especially with the FDA. Competitors can’t just buy the schematics; they have to rebuild the entire scientific and engineering foundation. This deep moat protects the company’s market position for the foreseeable future, making it a significant hurdle for any new entrant trying to catch up.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Structured for Exploitation\u003c\/h3\u003e\n\u003cp\u003eBrainsWay Ltd. is definitely organized to take full advantage of this asset. The operational metrics from Q3 2025 show they are scaling effectively. Shipping \u003cstrong\u003e90\u003c\/strong\u003e systems in the quarter, a \u003cstrong\u003e43%\u003c\/strong\u003e jump year-over-year, proves the sales, logistics, and service teams are aligned to deploy the technology efficiently. Furthermore, raising the full-year 2025 revenue guidance to a range of \u003cstrong\u003e$51 million – $52 million\u003c\/strong\u003e shows management has the internal processes and forecasting confidence to capitalize on market demand.\u003c\/p\u003e\n\u003cp\u003eThe organizational structure supports the technology through:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrong gross margin maintenance at \u003cstrong\u003e75%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSignificant growth in Net Profit, up \u003cstrong\u003e137%\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eFocus on multi-year lease agreements (about \u003cstrong\u003e70%\u003c\/strong\u003e of recent deals).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage: Sustained\u003c\/h3\u003e\n\u003cp\u003eWhen you combine a valuable, rare, and hard-to-copy asset with a company structure that is clearly executing on deployment and profitability, you land on a \u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e. The platform is the source of their premium margins and growth trajectory. If onboarding takes 14+ days, churn risk rises, but the current execution suggests they are managing that well. This technology isn't just giving them an edge today; it’s built to keep giving them an edge for years, provided they keep innovating on indications, like the recent NIH grant for alcohol use disorder studies.\u003c\/p\u003e\n\u003cp\u003eHere is a summary of the VRIO scoring:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eScore\/Implication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eDrives \u003cstrong\u003e$13.5 million\u003c\/strong\u003e in Q3 2025 revenue.\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eDeeper brain structure targeting is uncommon in the market.\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (I)\u003c\/td\u003e\n\u003ctd\u003eHigh engineering and scientific hurdle for competitors.\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eProven ability to ship \u003cstrong\u003e90\u003c\/strong\u003e systems and raise guidance.\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained Competitive Advantage\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBrainsWay Ltd. (BWAY) - VRIO Analysis: Extensive and Diversified FDA Clearances\/Clinical Evidence\n\u003c\/h2\u003e\n\u003cp\u003e\nThe foundation of sustained competitive advantage rests on the depth and breadth of regulatory and clinical validation for the Deep TMS™ platform.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e Having three FDA-cleared indications opens substantial patient pools and provides robust scientific validation.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003ePatient Population\/Context\u003c\/th\u003e\n\u003cth\u003eSupporting Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMajor Depressive Disorder (MDD)\u003c\/td\u003e\n\u003ctd\u003eAdults (previously 22 to 86 years) and Adolescents (15 to 21 years)\u003c\/td\u003e\n\u003ctd\u003eAdolescent data from 1,120 subjects across 35 centers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eObsessive-Compulsive Disorder (OCD)\u003c\/td\u003e\n\u003ctd\u003eAdults\u003c\/td\u003e\n\u003ctd\u003eBacked by pivotal clinical studies.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSmoking Addiction\u003c\/td\u003e\n\u003ctd\u003eAdults\u003c\/td\u003e\n\u003ctd\u003eBacked by pivotal clinical studies.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eRarity:\u003c\/strong\u003e Uniquely positioned as the first and only TMS company with three FDA-cleared indications supported by pivotal clinical studies demonstrating efficacy.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eImitability:\u003c\/strong\u003e High barrier due to time and capital required for clinical evidence generation. The adolescent MDD clearance was supported by a robust dataset collected between 2012 and 2024.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eOrganization:\u003c\/strong\u003e Active pursuit of label expansion demonstrates organizational commitment to leveraging existing clearances. The recent adolescent clearance expands the treatable depression age range significantly.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAdolescent MDD treatment involved 36 sessions over 4 to 6 weeks.\u003c\/li\u003e\n\u003cli\u003eAdolescent study demonstrated an average improvement of 12.1 points on the PHQ-9 scale.\u003c\/li\u003e\n\u003cli\u003eAdolescent study achieved a 66.1% response rate.\u003c\/li\u003e\n\u003cli\u003eThe Company reported revenue growth of 27.08% over the last twelve months.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained due to the established, multi-indication regulatory moat. The Company has also secured ninth FDA approval for the H7 Coil.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBrainsWay Ltd. (BWAY) - VRIO Analysis: Multi-Year Lease Revenue Model \u0026amp; Contracted Backlog\n\u003c\/h2\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThis structure creates predictable, recurring revenue streams, which analysts love to see.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate; while leasing exists, having approximately \u003cstrong\u003e70%\u003c\/strong\u003e of recent deals structured this way is uncommon in this sector.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eModerate; competitors can copy the model, but establishing the contractual trust takes time.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eYes, this is proven by the \u003cstrong\u003e$65 million\u003c\/strong\u003e in remaining performance obligations as of Q3 2025.\u003c\/p\u003e\n\n\u003cp\u003eSupporting financial metrics as of Q3 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRemaining Performance Obligations: \u003cstrong\u003e$65 million\u003c\/strong\u003e, a \u003cstrong\u003e37%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003cli\u003eRevenue for Q3 2025: \u003cstrong\u003e$13.5 million\u003c\/strong\u003e, a \u003cstrong\u003e29%\u003c\/strong\u003e increase year-over-year.\u003c\/li\u003e\n\u003cli\u003eAdjusted EBITDA for Q3 2025: \u003cstrong\u003e$2.0 million\u003c\/strong\u003e, an \u003cstrong\u003e81%\u003c\/strong\u003e increase year-over-year.\u003c\/li\u003e\n\u003cli\u003eTotal Installed Base: More than \u003cstrong\u003e1,600\u003c\/strong\u003e systems as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eCash and equivalents as of September 30, 2025: \u003cstrong\u003e$70.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary to Sustained.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Attribute\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate (Approx. \u003cstrong\u003e70%\u003c\/strong\u003e of recent deals are multi-year leases)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eModerate (Requires time to build contractual trust)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eYes (Supported by \u003cstrong\u003e$65 million\u003c\/strong\u003e in Remaining Performance Obligations)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary to Sustained\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eBrainsWay Ltd. (BWAY) - VRIO Analysis: Established Global Installed Base of Systems\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Justification\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003ePlatform for service revenue; Barrier to entry.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eSpecific scale in the Deep TMS niche.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eResult of years of sales execution.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eConsistent base growth and revenue structure.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eTotal installed base as of September 30, 2025: \u003cstrong\u003emore than 1,600\u003c\/strong\u003e systems.\u003c\/li\u003e\n\u003cli\u003eNet systems shipped in Q3 2025: \u003cstrong\u003e90\u003c\/strong\u003e systems.\u003c\/li\u003e\n\u003cli\u003eNet systems shipped in Q2 2025: \u003cstrong\u003e88\u003c\/strong\u003e systems.\u003c\/li\u003e\n\u003cli\u003ePercentage of recent customer engagements structured as multi-year lease agreements: Approximately \u003cstrong\u003e70%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRemaining Performance Obligations from multi-year contracts as of September 30, 2025: \u003cstrong\u003e$65 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRemaining Performance Obligations from multi-year contracts as of June 30, 2025: \u003cstrong\u003e$62 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Revenue: \u003cstrong\u003e$13.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ2 2025 Revenue: \u003cstrong\u003e$12.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Net Profit: \u003cstrong\u003e$1.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Gross Margin: \u003cstrong\u003e75%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents, and restricted cash as of September 30, 2025: \u003cstrong\u003e$70.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eBrainsWay Ltd. (BWAY) - VRIO Analysis: Patented Coil Design and System Architecture (IP)\n\u003c\/h2\u003e\n\u003cp\u003eThe core value proposition is rooted in the proprietary Deep TMS™ platform technology, protected by an evolving intellectual property portfolio.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eValue: Protection of Hardware Efficacy\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe patented Deep TMS H-coils feature a complex coil geometry engineered to enhance depth penetration, a key differentiator from conventional TMS systems.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSpecific patents, such as US Patent Number \u003cstrong\u003e8771163\u003c\/strong\u003e, detail systems including a helmet and coil designed to minimize unintended stimulation and surface charge accumulation.\u003c\/li\u003e\n\u003cli\u003ePatent Number \u003cstrong\u003e9636517\u003c\/strong\u003e relates to the use of TMS to modulate blood-brain barrier permeability.\u003c\/li\u003e\n\u003cli\u003eThe company explicitly notes that its device is difficult to duplicate regarding the \u003cstrong\u003enumber of coils and the OCD addition\u003c\/strong\u003e to the device.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eRarity: Uniqueness of Design and Indication\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe unique design enables the stimulation of deeper neuronal structures compared to other commercially available TMS systems.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP Element\u003c\/td\u003e\n\u003ctd\u003ePatent\/Feature Detail\u003c\/td\u003e\n\u003ctd\u003eDate\/Status Reference\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeep Penetration Coil\u003c\/td\u003e\n\u003ctd\u003eComplex coil geometry for enhanced depth penetration.\u003c\/td\u003e\n\u003ctd\u003eExclusive rights to Deep TMS technology, with subsequent patents by BrainsWay.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOCD Indication\u003c\/td\u003e\n\u003ctd\u003eSpecific addition to the device for Obsessive-Compulsive Disorder treatment.\u003c\/td\u003e\n\u003ctd\u003eNoted as hard to duplicate.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSystem Architecture\u003c\/td\u003e\n\u003ctd\u003eSystem including helmet, positioning portion, stimulator, and cooling system.\u003c\/td\u003e\n\u003ctd\u003ePatent granted on \u003cstrong\u003eJuly 8, 2014\u003c\/strong\u003e (US8771163).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eImitability: Defense Against Direct Copying\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003ePatent protection serves as the primary barrier to entry for direct replication of the core technology. The company holds exclusive rights to the Deep TMS technology, which was originally patented by the NIH, with subsequent patents secured by BrainsWay.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization: Active IP Management and Financial Scale\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe company actively manages its IP portfolio, which includes royalty obligations for licensed intellectual property.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eContractual obligations include royalties for the use of some intellectual property with Yeda and PHS.\u003c\/li\u003e\n\u003cli\u003eAs of \u003cstrong\u003eDecember 31, 2024\u003c\/strong\u003e, cash and cash equivalents and short-term deposits totaled \u003cstrong\u003e$69.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFull-year 2024 revenue reached \u003cstrong\u003e$41 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFor the third quarter of 2025, the company reported \u003cstrong\u003e$13.5 million\u003c\/strong\u003e in revenue and an installed base of \u003cstrong\u003e\u0026gt;1,600\u003c\/strong\u003e Deep TMS systems.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Sustained\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe combination of protected, superior technology and ongoing commercial traction supports a sustained advantage.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBrainsWay Ltd. (BWAY) - VRIO Analysis: Strategic Clinical Partnerships and Research Grants\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e External validation from bodies like the NIH de-risks future indications and attracts non-dilutive funding.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; securing a $2.5 million NIH grant for AUD research is a significant, non-routine achievement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; it relies on the quality of their science and relationships with top researchers.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes, they are actively pursuing these, including equity financing with Stella MSO, LLC.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary.\u003c\/p\u003e\n\u003cp\u003eThe company's engagement in strategic research is quantified by recent non-dilutive funding and equity investments:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Detail\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLatest NIH Grant Amount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAwarded over \u003cstrong\u003efive years\u003c\/strong\u003e for Alcohol Use Disorder (AUD) study.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrevious NIH Grant First-Year Budget\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.49M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAwarded last year for Stimulant Use Disorder (MUD) study.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAUD Study Enrollment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100 adults\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRandomized, double-blind, sham-controlled trial design.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAUD Study Protocol Intensity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30 treatment sessions\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3 treatments per day\u003c\/strong\u003e for \u003cstrong\u003e10 consecutive business days\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStella MSO, LLC Investment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMinority-stake equity financing investment.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStella MSO Clinic Footprint\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e20 clinics\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eServicing clinics across the U.S. and Israel.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organization's capacity to secure and execute on these partnerships is supported by its financial footing, as evidenced by recent operational metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 Revenue: \u003cstrong\u003e$13.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Gross Margin: \u003cstrong\u003e75%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Installed Base: More than \u003cstrong\u003e1,600 systems\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash, Cash Equivalents, etc. (as of Sept 30, 2025): \u003cstrong\u003e$70.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRemaining Performance Obligations: \u003cstrong\u003e$65 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eSpecific details of the AUD research partnership include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePrincipal Investigator Team: Led by Dr. Claudia Padula and Dr. Michelle Madore of \u003cstrong\u003eStanford University\u003c\/strong\u003e and the \u003cstrong\u003ePalo Alto Veterans Institute for Research\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTarget Coil: Utilization of BrainsWay's \u003cstrong\u003eH7 Coil\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eMechanistic Focus: Investigating neural activation in regions such as the \u003cstrong\u003edorsal Anterior Cingulate Cortex (dACC)\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eBrainsWay Ltd. (BWAY) - VRIO Analysis: High Gross Margin Profile\n\u003c\/h2\u003e\n\u003cp\u003e\nValue: A consistent gross margin of \u003cstrong\u003e75%\u003c\/strong\u003e (Q3 2025) shows strong pricing power and efficient cost management relative to the device's complexity. This is an improvement from \u003cstrong\u003e74%\u003c\/strong\u003e in the prior year period.\n\u003c\/p\u003e\n\u003cp\u003e\nThe high gross margin is supported by the recurring revenue component of the business model.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025\u003c\/th\u003e\n\u003cth\u003eQ3 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e75%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e74%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Profit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nRarity: High; this margin level is excellent for a hardware-heavy medical device company. The sustained high margin is supported by the business structure.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eApproximately \u003cstrong\u003e70%\u003c\/strong\u003e of recent customer engagements are structured as multi-year lease agreements.\u003c\/li\u003e\n\u003cli\u003eTotal installed base stood at more than \u003cstrong\u003e1,600\u003c\/strong\u003e systems as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eRemaining performance obligations totaled \u003cstrong\u003e$65 million\u003c\/strong\u003e from customers under multi-year contracts as of Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nImitability: Moderate; requires tight control over manufacturing and supply chain, which is hard to replicate quickly. The proprietary Deep TMS platform technology is a barrier.\n\u003c\/p\u003e\n\u003cp\u003e\nOrganization: Yes, maintaining \u003cstrong\u003e75%\u003c\/strong\u003e across multiple quarters shows process discipline. The company raised full-year 2025 guidance based on this momentum.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFull-year 2025 Revenue guidance midpoint raised to \u003cstrong\u003e$51 million – $52 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFull-year 2025 Operating Income guidance raised to \u003cstrong\u003e6% – 7%\u003c\/strong\u003e of revenue.\u003c\/li\u003e\n\u003cli\u003eFull-year 2025 Adjusted EBITDA guidance raised to \u003cstrong\u003e13% – 14%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nCompetitive Advantage: Sustained.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBrainsWay Ltd. (BWAY) - VRIO Analysis: Strong Balance Sheet and Financial Momentum\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003e$70.7 million\u003c\/strong\u003e cash, cash equivalents, and restricted cash position as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e, allows for strategic moves and supports a debt-free capital structure.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$70.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt\u003c\/td\u003e\n\u003ctd\u003eDebt-free\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Net Profit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; many growth-stage med-techs are cash-constrained, but BrainsWay is showing strong profitability trends, evidenced by a \u003cstrong\u003e75%\u003c\/strong\u003e Gross Margin in Q3 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLow; this is a direct result of past operational success and current market traction, including an installed base of more than \u003cstrong\u003e1,600\u003c\/strong\u003e systems as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eYes, they are organized to capitalize on this by raising 2025 revenue guidance to \u003cstrong\u003e$51 million – $52 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eShipped a net total of \u003cstrong\u003e90\u003c\/strong\u003e Deep TMS systems in Q3 2025, a \u003cstrong\u003e43%\u003c\/strong\u003e increase year-over-year.\u003c\/li\u003e\n\u003cli\u003eApproximately \u003cstrong\u003e70%\u003c\/strong\u003e of recent customer engagements are structured as multi-year lease agreements.\u003c\/li\u003e\n\u003cli\u003eHolds \u003cstrong\u003e$65 million\u003c\/strong\u003e in remaining performance obligations from customers under multi-year contracts.\u003c\/li\u003e\n\u003cli\u003eRaised full-year 2025 Adjusted EBITDA guidance to \u003cstrong\u003e13% – 14%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBrainsWay Ltd. (BWAY) - VRIO Analysis: Brand Recognition as a Mental Health Neurostimulation Leader\n\u003c\/h2\u003e\n\u003ch\u003e\u003ch\u003eValue: Being recognized as a global leader helps secure top-tier clinical sites and speeds up adoption by new clinicians.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe company is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The installed base of Deep TMS systems stands at more than \u003cstrong\u003e1,600\u003c\/strong\u003e systems as of September 30, 2025. The technology has treated over \u003cstrong\u003e100,000\u003c\/strong\u003e patients globally as of April 2021. BrainsWay holds \u003cstrong\u003ethree\u003c\/strong\u003e FDA-cleared indications.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity: Moderate; they are a leader in Deep TMS, but the broader neuromodulation space is competitive.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eBrainsWay is the first and only TMS company to obtain \u003cstrong\u003ethree\u003c\/strong\u003e FDA-cleared indications backed by pivotal clinical studies.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability: High; brand equity is built over time through consistent results and marketing.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eClinical evidence supports adoption, with approximately \u003cstrong\u003e80%\u003c\/strong\u003e of patients with MDD completing the full \u003cstrong\u003e30-session\u003c\/strong\u003e treatment protocol in trials. Real-world data for adolescent MDD showed a \u003cstrong\u003e66.1%\u003c\/strong\u003e response rate after \u003cstrong\u003e36 sessions\u003c\/strong\u003e across \u003cstrong\u003e35\u003c\/strong\u003e U.S. centers.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization: Yes, they consistently project this leadership status in their public communications, which helps defintely.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe company raised its full-year 2025 revenue guidance to between \u003cstrong\u003e$50 million\u003c\/strong\u003e and \u003cstrong\u003e$52 million\u003c\/strong\u003e, with an expected operating income margin of \u003cstrong\u003e4%\u003c\/strong\u003e to \u003cstrong\u003e5%\u003c\/strong\u003e and Adjusted EBITDA margin of \u003cstrong\u003e12%\u003c\/strong\u003e to \u003cstrong\u003e13%\u003c\/strong\u003e based on Q2 2025 results, and later raised guidance to \u003cstrong\u003e6%–7%\u003c\/strong\u003e operating income and \u003cstrong\u003e13%–14%\u003c\/strong\u003e Adjusted EBITDA based on Q3 2025 results.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Sustained.\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe company reported record quarterly revenue of \u003cstrong\u003e$13.5 million\u003c\/strong\u003e in Q3 2025, a \u003cstrong\u003e29%\u003c\/strong\u003e increase year-over-year, with \u003cstrong\u003e$65 million\u003c\/strong\u003e in remaining performance obligations as of September 30, 2025.\u003c\/p\u003e\n\u003cp\u003eFinancial and Operational Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYoY Revenue Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e27%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e29%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSystems Shipped (Net)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e81\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e88\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e90\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Installed Base\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,522\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;\u003cstrong\u003e1,600\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e75%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e75%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e75%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (End of Period)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$71.9 million\u003c\/strong\u003e (Mar 31)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$78.3 million\u003c\/strong\u003e (Jun 30)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$70.7 million\u003c\/strong\u003e (Sep 30)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eLeadership Indicators:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA Clearances: \u003cstrong\u003e3\u003c\/strong\u003e (MDD, OCD, Smoking Addiction).\u003c\/li\u003e\n\u003cli\u003eMDD Trial Completion Rate: Approximately \u003cstrong\u003e80%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAdolescent MDD Response Rate: \u003cstrong\u003e66.1%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSystems Installed Globally: Over \u003cstrong\u003e600\u003c\/strong\u003e reported previously.\u003c\/li\u003e\n\u003cli\u003eRemaining Performance Obligations (Sep 30, 2025): \u003cstrong\u003e$65 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516129861781,"sku":"bway-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/bway-vrio-analysis.png?v=1740154854","url":"https:\/\/dcf-model.com\/pt\/products\/bway-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}